An interventional study of 3RP-VHL in Von Hippel-Lindau Disease and Genetic Disorder, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in von Hippel-Lindau Disease with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. von Hippel-Lindau Disease · United States.
Among the 33 studies in von Hippel-Lindau Disease with a site in United States, this one is the 7th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2024, is one of 2 with no phase, and was the 31st registered.
55 studies on the registry are indexed under von Hippel-Lindau Disease; 23 are open to participants now.
Browse von Hippel-Lindau Disease studies →8 of the 33 studies in von Hippel-Lindau Disease with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 19 more countries
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Canada and 19 more countries
Ages 12+
National Cancer Institute (NCI) · Sites in United States
Ages 12+
St. Jude Children's Research Hospital · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 von Hippel-Lindau Disease studies recruiting now, 16 (80%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 1
First in 1997; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is above the median of 28 across 31 interventional studies indexed under von Hippel-Lindau Disease.
Median enrollment 15 across the 23 interventional studies, 300 across the 10 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 1 study filed under von Hippel-Lindau Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in von Hippel-Lindau Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05955014M.D. Anderson Cancer CenterData Collection Protocol for Patients With Von Hippel Lindau Disease | 2026-12-31 |
| NCT03401788Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | 2027-04-29 |
| NCT05737602Massachusetts General HospitalPromoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in von Hippel-Lindau Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.
The 3RP has not been carried out with VHL patients. As such, the investigators are looking to see if an adapted program, tailored to the needs of patients with VHL, is feasible, acceptable, and helpful in improving coping among individuals living with VHL.
This study is a two phase trial. Phase I is descriptive. It is comprised of conducting interviews with patients and caregivers to understand the challenges of living with VHL and patient's programatic needs. This information will be used to tailor the program for patients living with VHL. Phase II is a single-arm feasibility trial that will examine if the adapted program is feasible, acceptable, and helps promote stress management among VHL patients. To these means, we will test the adapted 3RP (3RP-VHL) in up to 40 patients living with VHL. Participants will complete surveys at baseline and post 3RP-VHL program completion. This record will reflect the trial component (Phase II) only, as feasibility and acceptability outcomes will be collected for this phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks. * Complete pre- and post-intervention surveys.
Behavioral: 3RP-VHL
An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
Also known as: Relaxation Response Resiliency Program for VHL
3RP-VHL Feasibility: Percent of Identified Eligibles Who Enroll
Percent of identified eligibles who were approached (hence given the opportunity to participate) who enroll (i.e., sign consent and complete baseline).
Time frame: Post-treatment completion (treatment is approximately 2 months)
3RP-VHL Feasibility: Proportion of Participants Completing the 3RP-VHL Program
Among those who initiated the program, this is the proportion of patients who completed the program (defined as completing 6 out of 8 sessions). Participants who complete at least 75% of the treatment sessions (6 out of 8 sessions) will be identified as treatment completers.
Time frame: Post-treatment completion (treatment is approximately 2 months)
3RP-VHL Acceptability: Five Questions
Acceptability will be assessed with five questions rated on a 4-point Likert scale (1=not at all to 4=very). More specifically, acceptability will be defined as ≥75% of responses rated at least 3/4 on enjoyableness, convenience, helpfulness, future use, and satisfaction.
Time frame: Post-treatment completion (treatment is approximately 2 months)
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for May 2027, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →